Low dose bisphenol A gene signature and endometrial cancer
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA579177 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR10337800.fastq.gz | Fastqsanger.gz | |||
| SRR10337801.fastq.gz | Fastqsanger.gz | |||
| SRR10337802.fastq.gz | Fastqsanger.gz | |||
| SRR10337803.fastq.gz | Fastqsanger.gz | |||
| SRR10337804.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 32 |
Similar Datasets
Project description:We found rats exposed to 250ug/kg/day BPA (BPA250) showed abnormal transition in estrous cycle at postnatal (PND) 90 whereas 25ug/kg/day BPA (BPA25) and BPA250 in 1-year-old rats showed prolonged estrus phase, suggesting that BPA25 and BPA250 may act like high dose EE2 (EE2-05) in disrupting normal estrous cycling. To dissect the underlying molecular mechanism, we performed RNA-sequencing on 1-year-old samples and found that both BPA25 and BPA250 groups shared similar gene signature. Pathway analysis suggested that 710 unique genes from both groups were associated with estradiol and also linked to female cancer as suggested by disease prediction analysis.
2020-12-22 | GSE139308 | GEO
Project description:Combination therapy with estrogen and a selective estrogen receptor modulator (SERM) is a promising approach to safely alleviate important side effects related to estrogen deficiency in women at high risk for breast cancer. Data related to endometrial safety of estrogen+SERM co-therapies are limited, however. The primary goal of this study was to evaluate the endometrial profile of low-dose E2 and Tam alone and in combination. In this study 16 postmenopausal female cynomolgus macaques were randomized to receive placebo, low-dose micronized estradiol (E2, 0.25 mg/1800 kcal), the SERM tamoxifen (Tam, 20 mg/1800 kcal), or E2+Tam in a parallel-arm design. Endometrial samples were collected after 4 months of treatment and used for microarray analysis.
2010-05-06 | E-GEOD-14518 | biostudies-arrayexpress
Project description:Expression data from mouse oocytes treated with low-dose bisphenol S
| PRJNA590354 | ENA
Project description:Combination therapy with estrogen and a selective estrogen receptor modulator (SERM) is a promising approach to safely alleviate important side effects related to estrogen deficiency in women at high risk for breast cancer. Data related to endometrial safety of estrogen+SERM co-therapies are limited, however. The primary goal of this study was to evaluate the endometrial profile of low-dose E2 and Tam alone and in combination.
2009-02-03 | GSE14518 | GEO
Project description:Bisphenol A (BPA) is used in the plastic industry as the monomer of polycarbonates and epoxy resins. Heat and changes in pH conditions lead to its leakage from the plastics in which it is incorporated. This largely contributes to the widespread exposure of the general population to this environmental contaminant. The exposure levels in humans are likely below the Tolerable Daily Intake (TDI: 50 µg/kg/day) and well below the No Observable Adverse Effect Level (NOAEL: 5000 µg/kg/day) defined from reprotoxicity studies. However, several studies suggest that BPA could induce deleterious effects specifically at low, environmentally relevant, doses. BPA has been described as an endocrine disruptor with estrogenic activity. Recently, it has been shown that BPA exposure has an impact on metabolic functions including stimulation of adipogenesis and of insulin production by the pancreas. Here, we investigated the effects of oral exposure to low (TDI) and high (NOAEL) doses of BPA on mouse liver transcriptome. Liver gene expression was measured from CD-1 mice (6 mice/group) exposed for 28 days to bisphenol A at doses 0 (controls), 50 (TDI or low dose) or 5000 µg/kg/day (NOAEL or high dose) via food contamination.
2011-09-20 | E-GEOD-26728 | biostudies-arrayexpress
Project description:The molecular profile of endometrial cancer has become an important tool in determining patient prognosis and their optimal adjuvant treatment. In addition to The Cancer Genome Atlas (TCGA), simpler tools have been developed, such as the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE). We attempted to determine a genetic signature to build a recurrence risk score in patients diagnosed with low- and intermediate-risk endometrial cancer. A case-control study was conducted. The eligible patients were women diagnosed with recurrence low- and intermediate-risk endometrial cancer between January 2009 and December 2014 at a single institution; the recurrence patients were matched to two nonrecurrence patients with the same diagnosis by age and surgical staging. Following RNA isolation of 51 cases, 17 recurrence and 34 nonrecurrence patients, the expression profile was determined using the nCounter® PanCancer Pathways Panel, which contains 770 genes. The expression profile was successfully characterized in 49/51 (96.1%) cases. We identified 12 genes differentially expressed between the recurrence and nonrecurrence groups. The ROC curve for each gene was generated, and all had AUCs higher than 0.7. After backward stepwise logistic regression, four genes were highlighted: FN1, DUSP4, LEF1, and SMAD9. The recurrence risk score was calculated, leading to a ROC curve of the 4-gene model with an AUC of 0.93, sensitivity of 100%, and specificity of 72.7%. We identified a four-gene signature that is associated the risk of recurrence in patients with low- and intermediate-risk endometrial cancer. This finding suggests a new prognostic factor in this poorly explored group of patients with endometrial cancer.
2021-07-27 | GSE178671 | GEO
Project description:Endocrine disrupting compounds (EDCs) have the potential to cause adverse effects on wildlife and human health. Two important EDCs are the synthetic estrogen 17a-ethynylestradiol (EE2) and bisphenol A (BPA) both of which are xenoestrogens (XEs) as they bind the estrogen receptor and disrupt estrogen physiology in mammals and other vertebrates. In recent years the influence of XEs on oncogenes, specifically in relation to breast and prostate cancer has been the subject of considerable study. In this study healthy primary human prostate epithelial cells (PrECs) were exposed to environmentally relevant concentrations of BPA (5nM and 25nM BPA) and interrogated using a whole genome microarray. Microarray data were analyzed using the Pipeline for Integrated Microarray Expression and Normalization Toolkit (PIMENTo) that provides (1) data pre-processing, (2) and normalization to remove the technical variability across arrays data, (3) data visualization, (4) background subtraction, (5) quality control, and (6) differential expression (DE) analysis using the Bioconductor package 'limma'. Exposure to 5 and 25nM BPA generated 8,876 and 9,525 differentially expressed (DE) genes respectively in treated PrECs. Exposure to EE2 had the greatest effect on the PrEC transcriptome (2,389 DE genes) and all three exposures shared 7,011 common DE genes. Together, the low and high dose of BPA affected 1,839 genes not shared with the EE2 exposure.
2021-01-01 | E-MTAB-7576 | biostudies-arrayexpress
Project description:To better understand the molecular basis of the reproductive health effects of bisphenol A (BPA) on humans, a genome-wide screening was applied to identify novel targets of low-dose bisphenol A exposure in huamn skin fibroblast cells (hSFCs) derived from hypospadias patient children. Three hSFCs were collected at National Research Institute for Child Health and Development, Japan. Gene expression profiles of hSFCs were measured at 24 hours after exposure to 10nM BPA, 0.01nM 17β-estradiol (E2) and 1nM 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Differentially expressed genes following chemical treatments were identified by unpaired Student’s t test with P values cut off by 0.05 and fold change of more than 1.2 and selected for the network generation and pathway analysis using Ingenuity Pathways Analysis (IPA) program. As the result, 71 genes (42 downregulated and 29 upregulated), 814 genes (371 downregulated and 443 upregulated), and 824 genes (344 downregulated and 480 upregulated) were identified significantly differently expressed in response to BPA, E2, and TCDD, respectively. The network analysis indicated that the most associated network fuctions of genes genes with altered expression profile derived from microarray analysis were “Endocrine System Disorders, Gastrointestinal Disease, Genetic Disorder”, “Cellular Growth and Proliferation, Skeletal and Muscular System Development and Function, Cell Cycle”, and “Post-Translational Modification, Genetic Disorder, Hematological Disease” in response to BPA, E2, and TCDD, respectively.
2012-01-13 | GSE35034 | GEO
Project description:To better understand the molecular basis of the reproductive health effects of bisphenol A (BPA) on humans, a genome-wide screening was applied to identify novel targets of low-dose bisphenol A exposure in huamn skin fibroblast cells (hSFCs) derived from hypospadias patient children. Three hSFCs were collected at National Research Institute for Child Health and Development, Japan. Gene expression profiles of hSFCs were measured at 24 hours after exposure to 10nM BPA, 0.01nM 17β-estradiol (E2) and 1nM 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Differentially expressed genes following chemical treatments were identified by unpaired Student’s t test with P values cut off by 0.05 and fold change of more than 1.2 and selected for the network generation and pathway analysis using Ingenuity Pathways Analysis (IPA) program. As the result, 71 genes (42 downregulated and 29 upregulated), 814 genes (371 downregulated and 443 upregulated), and 824 genes (344 downregulated and 480 upregulated) were identified significantly differently expressed in response to BPA, E2, and TCDD, respectively. The network analysis indicated that the most associated network fuctions of genes genes with altered expression profile derived from microarray analysis were “Endocrine System Disorders, Gastrointestinal Disease, Genetic Disorder”, “Cellular Growth and Proliferation, Skeletal and Muscular System Development and Function, Cell Cycle”, and “Post-Translational Modification, Genetic Disorder, Hematological Disease” in response to BPA, E2, and TCDD, respectively. Gene expression profiles of 3 hSFCs derived from hypospadias patient children were measured at 24 hours after exposure to 10nM BPA, 0.01nM E2 and 1nM TCDD.
2012-01-13 | E-GEOD-35034 | biostudies-arrayexpress
Project description:Dose-dependent transcriptomic responses of zebrafish embryos to Bisphenol A
| PRJNA453567 | ENA